共 216 条
[21]
Housman TS(2008)Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure Blood 112 4445-4451
[22]
Jorizzo JL(2006)Toxicity profile of the immunomodulatory thalidomide analogue, Lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies Eur J Cancer 42 2318-2325
[23]
McCarty MA(2009)Lenalidomide for the treatment of resistant discoid lupus erythematosus Arch Dermatol 145 303-306
[24]
Grummer SE(2012)Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flare J Am Acad Dermatol 66 571-582
[25]
Fleischer AB(2005)The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus J Invest Dermatol 125 889-894
[26]
Sutej PG(2002)Systemic lupus erythematosus disease activity index 2000 J Rheumatol 29 288-291
[27]
Kyriakis KP(1982)The 1982 revisited criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 1271-1277
[28]
Kontochristopoulus GJ(2009)Drugs for discoid lupus erythematosus Cochrane Database Syst Rev 4 CD002954-192
[29]
Panteleos DN(2007)Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study Br J Dermatol 156 191-1370
[30]
Knop J(2009)A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus Br J Dermatol 161 1365-961